Green Cross Concludes Takeover Deal Of Innocell; Looks To Overseas Markets For Growth
This article was originally published in PharmAsia News
Executive Summary
Korea’s Green Cross to continue development of Innocell’s Immuncell-LC cancer cell therapy after becoming the major shareholder of the troubled company.